PLOS One · Nov 16, 2026
Guideline-directed discharge medication patterns and post-discharge outcomes in older patients with acute coronary syndrome and multivessel coronary disease: A real-world observational study
By Dang HNN, Nguyen HM, Tran PT et al.
Background: Guideline-directed medical therapy is central to secondary prevention after acute coronary syndrome (ACS), but recommendations are usually framed at the medication-class level. In discharge practice, clinicians must select individual agents, especially in older patients with multivessel coronary disease. This study described discharge prescribing patterns and examined associations between within-class medication choices and short-term major adverse cardiovascular events (MACE). Methods: This prospective, multicenter, real-world observational cohort included 277 patients aged ≥60 years with ACS and multivessel coronary disease. The primary outcome was 3-month MACE. Risk ratios (RRs) were estimated using modified Poisson regression with robust standard errors. Results: Core secondary prevention therapies were frequently prescribed, including dual antiplatelet therapy in 99.3% and statins in 99.6%. In fully adjusted within-class analyses, ticagrelor versus clopidogrel had an RR of 0.70 for short-term MACE (95% CI, 0.40–1.21; P = 0.203), empagliflozin versus dapagliflozin had an RR of 1.55 (95% CI, 0.93–2.59; P = 0.094), and rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79–1.85; P = 0.372). Exploratory subgroup analyses showed nominal signals for ticagrelor versus clopidogrel among patients with frailty (RR, 0.36; 95% CI, 0.15–0.89; P = 0.026), and for empagliflozin versus dapagliflozin among patients with left ventricular ejection fraction <50% (RR, 1.86; 95% CI, 1.07–3.21; P = 0.027) and non-ST-segment elevation acute coronary syndrome (RR, 2.26; 95% CI, 1.05–4.88; P = 0.037). However, none remained statistically significant after adjustment for multiple comparisons. Conclusions: In older patients with ACS and multivessel disease, secondary prevention was widely implemented. Within-class comparisons showed no clear short-term MACE differences, while subgroup signals require validation.
doi.org/10.1371/journal.pone.0355518Open accessPubMed 43038200Interventions